Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
=== Allegations of steroid use and National Baseball Hall of Fame === Bagwell was eligible for induction into the Baseball Hall of Fame for the first time in 2011. Speculation abounded that some baseball writers initially refrained from voting for Bagwell on the premise that he used performance-enhancing drugs, since most of his playing career took place during what is commonly referred to as "the steroid era." In spite of the speculation, as of 2016, no concrete evidence has surfaced linking him to the use of performance-enhancing drugs. However, one report indicates that he disclosed use of androstenedione to a Houston Chronicle reporter in 1998. At that time, neither the FDA nor MLB had banned its use. Bagwell has not been connected with any of the 104 positive samples in the 2003 survey tests that were leaked. Bagwell was not among the 89 players named in the Mitchell Report released in 2007. Longtime Atlanta Braves manager Bobby Cox said the following about Bagwell: "Jeff Bagwell was [in Houston] for so long and starred every year. For me a guy that dominated like that for one team, even in the league stats through the years. His are up there with anybody's. I would put him in right away. So he would get my vote on the first ballot." Still, in spite of the speculation that Bagwell used performance-enhancing drugs, San Francisco Chronicle sportswriter Bruce Jenkins wrote that Bagwell did not have the credentials to be in the Hall of Fame. In July 2015, he acknowledged "that many are suspicious of Bagwell—without proof, as you say.
== Medical significance == About half of people receiving radiation therapy in the head and neck region experience dry mouth (xerostomia or hyposalivation) as a side effect, which can be irreversible for high doses (>60 Gray). Early in treatment, direct damage is primarily to the serous acinar cells of the serous acini, but the therapy can also damage the surrounding blood vessels and nerves. This can be mitigated through parotid/submandibular gland sparing intensity-modulated radiotherapy (IMRT), though damage to the minor salivary glands is hard to avoid. When reversible, salivary gland function typically takes 6-12 months to recover.
Radiation therapy is usually reserved for people who have tumours remaining after surgery. These people often also receive medication to lower GH levels. Radiation therapy is given in divided doses over four to six weeks. This treatment lowers GH levels by about 50 percent over 2 to 5 years. People monitored for more than 5 years show significant further improvement. Radiation therapy causes a gradual loss of production of other pituitary hormones with time. Loss of vision and brain injury, which have been reported, are very rare complications of radiation treatments.
Sources: en.wikipedia.org
== As controlled drug == Thebaine is controlled under international law, is listed as a Class A drug under the Misuse of Drugs Act 1971 in the United Kingdom, is controlled as an analog of a Schedule II drug per the Analog Act in the United States, and is controlled with its derivatives and salts, as a Schedule I substance of the Controlled Drugs and Substances Act in Canada. The 2013 US Drug Enforcement Administration (DEA) aggregate manufacturing quota for thebaine (ACSCN 9333) was unchanged from the previous year at 145 metric tons.
==== Eulipotyphlan research ==== Valenzuela et al. (2026) study the evolution of the postcranial skeleton in the lineage of Nesiotites from the Pliocene to the Holocene, reporting that members of the studied lineage underwent a size shift throughout their evolutionary history but retained adaptations to terrestrial generalist locomotion. A study on the composition and evolution of Miocene erinaceid assemblages from the Daroca-Calamocha area (Spain) is published by Cailleux et al. (2026). Cailleux (2026) identifies common dental pathologies in the fossil material of Galerix stehlini from the Miocene strata from La Grive-Saint-Alban (France), and interprets their recurrence as possibly linked to small population size linked to habitat fragmentation.
Atrophy is the partial or complete wasting away of a part of the body. Causes of atrophy include mutations (which can destroy the gene to build up the organ), poor nourishment, poor circulation, loss of hormonal support, loss of nerve supply to the target organ, excessive amount of apoptosis of cells, and disuse or lack of exercise or disease intrinsic to the tissue itself. In medical practice, hormonal and nerve inputs that maintain an organ or body part are said to have trophic effects. A diminished muscular trophic condition is designated as atrophy. Atrophy is reduction in size of cell, organ or tissue, after attaining its normal mature growth. In contrast, hypoplasia is the reduction in the cellular numbers of an organ, or tissue that has not attained normal maturity. Atrophy is the general physiological process of reabsorption and breakdown of tissues, involving apoptosis. When it occurs as a result of disease or loss of trophic support because of other diseases, it is termed pathological atrophy, although it can be a part of normal body development and homeostasis as well.
Sources: en.wikipedia.org
The pericardium (pl. pericardia), also called pericardial sac, is a fluid filled sac containing the heart and the roots of the great vessels. It has three layers, an outer layer made of strong inelastic connective tissue (fibrous pericardium), and a double-layered inner membrane serous membrane (serous pericardium), between which the pericardial fluid is contained. It encloses the pericardial cavity, which contains pericardial fluid, and defines the middle mediastinum. It separates the heart from interference of other structures, protects it against infection and blunt trauma, and lubricates the heart's movements.
==== Sales channels and measurement ==== Approximately 30–50% of total e-cigarettes sales are handled on the internet. In the United States, the Federal Trade Commission reported that, for major manufacturers it surveyed, direct sales accounted for 8.13% of reported e-cigarette sales in 2019 and 7.09% in 2020, with most reported sales occurring indirectly through retail channels. Retail-sales datasets used in market reporting may also exclude online and specialty vape-shop channels. Industry structure and supply chains Established tobacco companies have a significant share of the e-cigarette market. As of 2018, 95% of e-cigarette devices were made in China, mainly in Shenzhen. More recent policy reporting and official analysis continue to link a substantial share of product supply to imported devices, including from China, as well as to cross-border e-commerce channels for some products. Chinese companies' market share of e-liquid is low. In 2014, online and offline sales started to increase. Since combustible cigarettes are relatively inexpensive in China a lower price may not be a large factor in marketing vaping products over there. Large tobacco retailers are leading the cigalike market. "We saw the market's sudden recognition that the cigarette industry seems to be in serious trouble, disrupted by the rise of vaping," Mad Money's Jim Cramer stated April 2018.
=== Without a hydrogen on the α-carbon === All proteinogenic amino acids have at least one hydrogen on the α-carbon. Glycine has two hydrogens, and all others have one hydrogen and one side-chain. Replacement of the remaining hydrogen with a larger substituent, such as a methyl group, distorts the protein backbone. In some fungi α-aminoisobutyric acid is produced as a precursor to peptides, some of which exhibit antibiotic properties. This compound is similar to alanine, but possesses an additional methyl group on the α-carbon instead of a hydrogen. It is therefore achiral. Another compound similar to alanine without an α-hydrogen is dehydroalanine, which possesses a methylene sidechain. It is one of several naturally occurring dehydroamino acids.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.